AI assistant
BIOMARIN PHARMACEUTICAL INC — Director's Dealing 2012
Nov 9, 2012
30583_dirs_2012-11-09_30dd2247-3a72-4688-be57-7a1bca866d7b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK: 0001048477
Period of Report: 2012-11-07
Reporting Person: BIENAIME JEAN JACQUES (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2012-11-07 | Common Stock | S | 2000 | $47.7304 | Disposed | 172691 | Direct |
| 2012-11-07 | Common Stock | S | 3000 | $47.003 | Disposed | 169691 | Direct |
| 2012-11-09 | Common Stock | S | 2000 | $48.422 | Disposed | 167691 | Direct |
Footnotes
F1: The price in Column 4 is a weighted average price. The prices actually received ranged from $47.731 to $47.736. The reporting person will provide to the issue, any security holder of the issuer, or SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F2: The price in Column 4 is a weighted average price. The prices actually received ranged from $47.001 to $47.062. The reporting person will provide to the issue, any security holder of the issuer, or SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3: The price in Column 4 is a weighted average price. The prices actually received ranged from $48.401 to $48.45. The reporting person will provide to the issue, any security holder of the issuer, or SEC staff, upon request, information regarding the number of shares sold at each price within the range.